Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.

IF 3 3区医学 Q2 ONCOLOGY

Investigational New Drugs Pub Date : 2024-02-01 Epub Date: 2023-11-16 DOI:10.1007/s10637-023-01406-y

Guoliang Yao, Jianyong Yuan, Qianqian Duan, Yuan Tan, Qin Zhang, Dongsheng Chen, Jingbo Chen

{"title":"Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.","authors":"Guoliang Yao, Jianyong Yuan, Qianqian Duan, Yuan Tan, Qin Zhang, Dongsheng Chen, Jingbo Chen","doi":"10.1007/s10637-023-01406-y","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in immune checkpoint inhibitors (ICIs) have enabled more effective treatment for individuals with various types of solid tumors. Given the improved survival benefit and acceptable safety profile of ICIs in advanced gastric cancer, there is plenty of interest in the use of ICIs in the neoadjuvant setting with curative intent. Theoretically, immunoneoadjuvant with ICIs could boost the levels of endogenous tumor antigen present in the tumor to enhance T-cell priming and further enhance systemic immunity. This systemic immune response may improve the detection and elimination of the disseminated micrometastatic tumors beyond the resected tumor, which are sources of postsurgical relapse. Numerous clinical studies have begun to explore the application of ICIs in neoadjuvant treatment of gastric cancer. This article reviews the progress in the use of ICI monotherapy and in combination with alternative therapies for the treatment of gastric cancer to aid in the development of gastric cancer immunoneoadjuvant therapy and improve the overall therapeutic benefit.</p>","PeriodicalId":14513,"journal":{"name":"Investigational New Drugs","volume":" ","pages":"1-13"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Investigational New Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10637-023-01406-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Advances in immune checkpoint inhibitors (ICIs) have enabled more effective treatment for individuals with various types of solid tumors. Given the improved survival benefit and acceptable safety profile of ICIs in advanced gastric cancer, there is plenty of interest in the use of ICIs in the neoadjuvant setting with curative intent. Theoretically, immunoneoadjuvant with ICIs could boost the levels of endogenous tumor antigen present in the tumor to enhance T-cell priming and further enhance systemic immunity. This systemic immune response may improve the detection and elimination of the disseminated micrometastatic tumors beyond the resected tumor, which are sources of postsurgical relapse. Numerous clinical studies have begun to explore the application of ICIs in neoadjuvant treatment of gastric cancer. This article reviews the progress in the use of ICI monotherapy and in combination with alternative therapies for the treatment of gastric cancer to aid in the development of gastric cancer immunoneoadjuvant therapy and improve the overall therapeutic benefit.

Abstract Image

查看原文本刊更多论文

胃癌免疫检查点抑制剂的免疫辅助治疗:一个新兴的例子:胃癌的免疫辅助治疗。

免疫检查点抑制剂(ICIs)的进展使各种类型实体瘤的个体治疗更加有效。鉴于ICIs在晚期胃癌中改善的生存获益和可接受的安全性，在具有治疗目的的新辅助设置中使用ICIs有很多兴趣。理论上，免疫佐剂加入ICIs可以提高肿瘤内存在的内源性肿瘤抗原水平，从而增强t细胞的启动，进一步增强全身免疫。这种全身免疫反应可以提高对切除肿瘤外弥散性微转移性肿瘤的检测和消除，这是术后复发的来源。大量临床研究开始探索ICIs在胃癌新辅助治疗中的应用。本文综述了ICI单药及联合其他替代疗法治疗胃癌的研究进展，以促进胃癌免疫辅助治疗的发展，提高整体治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Investigational New Drugs 医学-药学

CiteScore

7.60

自引率

0.00%

发文量

121

审稿时长

1 months

期刊介绍： The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.